drugset / Trial / NCT04045028
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).
Timeline
- Start
- 2019-07-22
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
Outcome
Outcome not reported
Stopped (Enrollment): “Slow recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Subcutaneous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |